Voyager Therapeutics, Inc.
VYGR
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington'sā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.30
Price-2.80%
-$0.09
1Y
Price
Market Cap
$199.088m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1040.9%
EBITDA Margin-1077.4%
Net Profit Margin-1289.4%
Free Cash Flow Margin-1040.9%
EBITDA Margin-1077.4%
Net Profit Margin-1289.4%
Free Cash Flow MarginRevenue
$36.494m
-9.6%
1y CAGR-42.4%
3y CAGR+96.0%
5y CAGREarnings
-$116.637m
+2.6%
1y CAGR-76.9%
3y CAGR+38.6%
5y CAGREPS
-$1.98
+2.9%
1y CAGR-71.9%
3y CAGR+32.5%
5y CAGRBook Value
$173.669m
$219.325m
Assets$45.656m
Liabilities$34.566m
DebtDebt to Assets
15.8%
-0.3x
Debt to EBITDAFree Cash Flow
-$129.943m
+3.8%
1y CAGR-246.2%
3y CAGR-35.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company